Atazanavir
Introduction
Atazanavir is an antiretroviral medication primarily used in the treatment of human immunodeficiency virus (HIV) infection. It belongs to the class of drugs known as protease inhibitors.
Biological Basis
Atazanavir functions by selectively inhibiting the HIV-1 protease enzyme. This enzyme is crucial for the viral life cycle, as it is responsible for cleaving precursor polyproteins into functional proteins required for the assembly of new, infectious viral particles. By blocking this process, atazanavir prevents the maturation of HIV, leading to the production of immature, non-infectious viral progeny.
Clinical Relevance
As a protease inhibitor, atazanavir is a key component of highly active antiretroviral therapy (HAART) regimens for individuals living with HIV/AIDS. Its use aims to reduce the viral load to undetectable levels, improve immune function, and prevent the progression of HIV disease and opportunistic infections. Atazanavir is often co-administered with other antiretroviral drugs to enhance efficacy and minimize the development of drug resistance. Clinical considerations for atazanavir include potential drug-drug interactions and side effects, such as hyperbilirubinemia, which can cause yellowing of the skin and eyes.
Social Importance
The development and availability of drugs like atazanavir have profoundly impacted the global response to the HIV/AIDS epidemic. By effectively suppressing viral replication, atazanavir contributes to improving the health and quality of life for millions of people with HIV, transforming a once rapidly fatal disease into a manageable chronic condition. Furthermore, achieving an undetectable viral load through consistent treatment significantly reduces the risk of HIV transmission, contributing to public health efforts to prevent new infections. The ongoing challenge remains ensuring equitable access to such life-saving medications and addressing issues of adherence and drug resistance worldwide.
Methodological and Statistical Considerations
Current genome-wide association studies (GWAS) often face limitations related to statistical power and the comprehensive coverage of genetic variation. Many studies, even with substantial sample sizes, may lack sufficient power to reliably detect genetic effects that contribute modestly to phenotypic variation, potentially leading to false negative findings. [1] Furthermore, the extensive number of statistical tests performed in GWAS increases the risk of false positive associations, necessitating stringent significance thresholds and external replication for validation. [2] The reliance on imputation based on reference panels like HapMap, while expanding SNP coverage, introduces a degree of uncertainty, with reported imputation error rates and varying confidence levels for imputed SNPs across different studies. [3]
The scope of genetic variants analyzed in many GWAS may not fully capture the complex genetic architecture of traits. Early generation SNP arrays provided only partial coverage of all common genetic variations, meaning that some causal genes or variants could be missed due to a lack of directly genotyped or reliably imputed markers in strong linkage disequilibrium. [2] Additionally, meta-analyses often employ fixed-effects models, which assume no heterogeneity between studies; if significant heterogeneity exists, this assumption could lead to biased combined estimates and impact the interpretation of overall effect sizes. [3] These methodological constraints highlight the ongoing need for larger, more diverse cohorts and advanced analytical methods to enhance the precision and completeness of genetic discoveries.
Population Specificity and Generalizability
A significant limitation of many genetic studies is their focus on specific populations, which can restrict the generalizability of findings to broader ancestral groups. Several studies primarily included individuals of Caucasian descent or specific founder populations, which may not accurately reflect genetic associations or effect sizes in other diverse populations. [4] Although efforts are made to mitigate population stratification through statistical adjustments or family-based designs, residual stratification can still confound results, leading to spurious associations that are not truly genetic in origin. [5]
Furthermore, genetic effects can be context-dependent, varying across different demographic groups or sexes. For instance, some genetic variants may exhibit associations with phenotypes exclusively in males or females, which could be overlooked when analyses are performed on sex-pooled data to avoid worsening the multiple testing problem [6] This underscores the importance of conducting studies in diverse populations and performing sex-specific analyses to uncover the full spectrum of genetic influences and ensure that findings are broadly applicable across human populations.
Phenotypic Complexity and Unexplored Interactions
The complexity of phenotype measurement and the interplay between genetic and environmental factors present substantial challenges in interpreting GWAS findings. Variability in assay methodologies and demographic characteristics across different study populations can lead to differences in mean phenotype levels, complicating direct comparisons and meta-analyses. [3] While averaging repeated measurements of traits can reduce random error, it might also obscure transient or dynamic biological processes, potentially masking relevant genetic associations with acute changes or specific states. [2]
Crucially, most GWAS do not comprehensively investigate gene-environment interactions, despite evidence that environmental factors can modulate genetic effects on phenotypes. [2] The absence of such analyses means that observed genetic associations might be highly context-specific, and their true impact could be underestimated or misinterpreted without considering environmental influences. Moreover, GWAS typically identify SNPs in linkage disequilibrium with causal variants, rather than the causal variants themselves, and the exact functional mechanisms by which these variants influence protein levels or other biological processes, potentially through copy number variations or altered gene expression, often require extensive follow-up investigations. [7]
Variants
SORCS2 (Sortilin-Related VPS10 Domain Containing Receptor 2) is a member of the Vps10p-domain receptor family, which are primarily known for their roles in protein sorting and trafficking within cells. These receptors are involved in various cellular processes, including neuronal development, synaptic function, and potentially metabolic regulation. While the precise functional impact of rs73208473 is still being investigated, variants in SORCS2 could potentially influence the expression or function of this receptor, thereby affecting its role in cellular signaling or protein transport pathways. Such alterations might indirectly impact metabolic processes or drug responses, though direct associations with specific drug toxicities like those of atazanavir require further study . [8], [9]
Variants in the UGT1A1 gene, which encodes UDP-glucuronosyltransferase 1 family polypeptide A1, are crucial determinants of bilirubin metabolism. This enzyme is primarily responsible for conjugating bilirubin, making it water-soluble for excretion from the body. Genetic variations, such as rs741159, rs726017, and rs6752792, can reduce UGT1A1 enzyme activity, leading to elevated unconjugated bilirubin levels, a condition known as hyperbilirubinemia. [1] Atazanavir, an antiretroviral drug, is a known inhibitor of UGT1A1, and individuals carrying certain UGT1A1 polymorphisms may be more susceptible to atazanavir-induced hyperbilirubinemia due to their already compromised bilirubin clearance capacity. While some studies did not find a significant association between these specific SNPs and bilirubin concentrations, the role of UGT1A1 variations in drug-induced hyperbilirubinemia is well-established. [1]
Several genetic loci influence lipid levels, which are relevant to the dyslipidemia often associated with atazanavir therapy and increased cardiovascular risk. For instance, variants in the HMGCR gene, such as rs3846662, have been linked to LDL-cholesterol levels and can affect the alternative splicing of exon 13, potentially altering the function or levels of HMG-CoA reductase, a key enzyme in cholesterol synthesis. [10] Polymorphisms within the APOA1-APOC3-APOA4-APOA5 gene cluster, including rs6589566 and rs17482753, are strongly associated with serum triglyceride levels and influence the metabolism of various lipoproteins. [8] Similarly, variants like rs12740374 in regions containing CELSR2, PSRC1, and SORT1 genes have been identified as contributing to LDL-cholesterol concentrations, highlighting their collective role in polygenic dyslipidemia. [9] These genetic predispositions, when combined with drug effects like those of atazanavir, can significantly modulate an individual's lipid profile and overall cardiovascular risk.
Key Variants
| RS ID | Gene | Related Traits |
|---|---|---|
| rs73208473 | SORCS2 | atazanavir measurement |
References
[1] Benjamin EJ et al. Genome-wide association with select biomarker traits in the Framingham Heart Study. BMC Med Genet. 2007 Oct 2;8 Suppl 1:S11.
[2] Vasan, Ramachandran S., et al. "Genome-wide association of echocardiographic dimensions, brachial artery endothelial function and treadmill exercise responses in the Framingham Heart Study." BMC Medical Genetics, vol. 8, 2007.
[3] Yuan, Xin, et al. "Population-based genome-wide association studies reveal six loci influencing plasma levels of liver enzymes." American Journal of Human Genetics, vol. 83, no. 4, 2008, pp. 520–528.
[4] Dehghan, Abbas, et al. "Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study." Lancet, vol. 372, no. 9654, 2008, pp. 1823–1831.
[5] Benyamin, Beben, et al. "Variants in TF and HFE explain approximately 40% of genetic variation in serum-transferrin levels." American Journal of Human Genetics, vol. 84, no. 1, 2009, pp. 60–65.
[6] Yang, Qiong, et al. "Genome-wide association and linkage analyses of hemostatic factors and hematological phenotypes in the Framingham Heart Study." BMC Medical Genetics, vol. 8, 2007.
[7] Sabatti, Chiara, et al. "Genome-wide association analysis of metabolic traits in a birth cohort from a founder population." Nature Genetics, vol. 42, no. 1, 2010, pp. 31–36.
[8] Wallace C. Genome-wide association study identifies genes for biomarkers of cardiovascular disease: serum urate and dyslipidemia. Am J Hum Genet. 2008 Jan;82(1):138-49.
[9] Kathiresan S et al. Common variants at 30 loci contribute to polygenic dyslipidemia. Nat Genet. 2008 Dec;40(12):1426-35.
[10] Burkhardt R et al. Common SNPs in HMGCR in micronesians and whites associated with LDL-cholesterol levels affect alternative splicing of exon13. Arterioscler Thromb Vasc Biol. 2008 Nov;28(11):2095-101.